Skip to Content
Merck
  • The head, neck, and systemic manifestations of levamisole-adulterated cocaine use.

The head, neck, and systemic manifestations of levamisole-adulterated cocaine use.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons (2013-01-10)
Kelly R Magliocca, Neysa Alice Coker, Sareeta R Parker
ABSTRACT

Systemic complications of levamisole-adulterated cocaine (LAC) use have recently been described. The objective of this review is to increase awareness of these manifestations among oral and maxillofacial surgeons. LAC exposure through inhalation, nasal insufflation, or injection can induce cutaneous vasculopathy and hematologic abnormalities such as neutropenia or agranulocytosis. Unlike other vasculopathies involving the skin, LAC-induced vascular injury frequently manifests with purpuric and necrotic lesions that involve the face and ears. Oral manifestations have also been reported but are not yet well characterized. The aforementioned hematologic manifestations are not uncommon, and patients exposed to LAC are potentially at higher risk for infectious complications. When manifestations of LAC affect the head, neck, and oral cavity, oral and maxillofacial surgeons may be the first providers to encounter the patient. Early recognition of the clinical signs and laboratory abnormalities will better allow for distinguishing LAC-related effects from various clinical mimics, will facilitate appropriate patient management, and may further contribute to the understanding of the biological effects of LAC.

MATERIALS
Product Number
Brand
Product Description

Supelco
(−)-Levamisole hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Levamisol hydrochloride, VETRANAL®, analytical standard
Levamisole hydrochloride for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(−)-Tetramisole hydrochloride, ≥99% (GC)
Levamisole hydrochloride, European Pharmacopoeia (EP) Reference Standard